Binds Plasma Protein, Serum Protein, Or Fibrin (e.g., Clotting Factor, Fibrinolytic Factor, Complement Factor, Immunoglobulin, Apolipoprotein, Etc.) Patents (Class 530/389.3)
  • Patent number: 9017957
    Abstract: An object of the present invention is to provide an antibody that can be stably supplied and can react with prostasin under non-denaturation and denaturation conditions, and an antigen peptide for preparation of the antibody. The present invention relates to a peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 or a peptide consisting of an amino acid sequence that has a deletion, a substitution, or an addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1 and having antigenicity of prostasin. Furthermore, the present invention relates to an antibody prepared using the peptide as an antigen.
    Type: Grant
    Filed: May 1, 2007
    Date of Patent: April 28, 2015
    Assignees: Hitachi Chemical Company, Ltd., Kimio Tomita, Kenichiro Kitamura
    Inventors: Hiromi Iijima, Noriya Ohta, Kimio Tomita, Kenichiro Kitamura
  • Patent number: 9012154
    Abstract: The present invention relates to methods for detecting Ficolin-3 dependent activation of the lectin pathway of complement, methods for identifying abnormalities in Ficolin-3, and methods for screening for deficiencies/and or identifying abnormalities in any downstream components of the Ficolin-3 dependent activation of the lectin pathway of 5 complement using an acetylated Ficolin-3 ligand, said methods generally comprising the steps of: (a) providing a sample of blood, serum, plasma, another body fluid or an extract thereof; (b) (optionally) preventing in the sample activation of the classical pathway and/or the alternative pathway and/or any non-Ficolin-3 mediated activation of the lectin pathway; (c) acetylating a molecule; (d) contacting said acetylated molecule 10 with said sample, in conditions that permit specific binding of Ficolin-3 to said acetylated molecule, and, (e) detecting and quantifying specific binding of the Ficolin-3 to said acetylated molecule, (f) determining in the sample complement ac
    Type: Grant
    Filed: June 9, 2010
    Date of Patent: April 21, 2015
    Assignees: Rigshospitalet, University of Copenhagen
    Inventors: Peter Garred, Christian Honore
  • Patent number: 9000134
    Abstract: The invention provides reagents and methods for diagnosing kidney disease in a human or animal.
    Type: Grant
    Filed: May 12, 2008
    Date of Patent: April 7, 2015
    Inventors: Wallace B. Haigh, Donald L. Very, Jr.
  • Publication number: 20150087813
    Abstract: The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity.
    Type: Application
    Filed: February 5, 2014
    Publication date: March 26, 2015
    Applicant: Domantis Limited
    Inventors: Kevin MOULDER, Ian Tomlinson
  • Patent number: 8945860
    Abstract: The present invention relates to compositions and highly sensitive methods for the detection of biotechnology product residual when monitoring product carry over and/or for cleaning verification in the manufacture of biotechnology products. In particular, the present invention is directed to immunoassays wherein one or more capture antibodies, or antigen binding fragments thereof, are used to detect residuals associated with the production of biotechnology products.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: February 3, 2015
    Assignee: Abbvie Inc.
    Inventors: Lihua Yang, Natarajan Ramasubramanyan
  • Patent number: 8927220
    Abstract: A protein used as a biomarker for diagnosing IgA nephropathy and TGBM (thin-glomerular-basement-membrane) using urine through a target proteomics method. A diagnosis biomarker protein and a kit for diagnosing IgA nephropathy and TGBM and predicting progress of the nephropathy in advance using the protein are provided. The degree of the progression of the disease can be grasped by detecting IgA nephropathy and TGBM, enabling early diagnosis and confirming progress from the patient's urine. In addition, a monoclonal antibody produced based on the diagnosis biomarker protein can be used for an immunoassay kit (ELISA, antibody coated tube test, lateral-flow test, potable biosensor). The monoclonal antibody is used in early diagnosis and progression detection of IgA nephropathy and development of a novel drug for the purpose of treatment.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: January 6, 2015
    Assignee: Kyungpook National University Industry-Academic Cooperation Foundation
    Inventors: Moon Chang Baek, Pyong Gon Moon, Yong Lim Kim
  • Patent number: 8921528
    Abstract: Drug compositions, fusions and conjugates are provided. The drug fusions and conjugates contain a therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The drug compositions, fusions and conjugates have a longer in vivo half-life in comparison with the unconjugated or unfused therapeutic or diagnostic agent.
    Type: Grant
    Filed: May 31, 2005
    Date of Patent: December 30, 2014
    Assignee: Domantis Limited
    Inventors: Lucy J. Holt, Ian M. Tomlinson
  • Publication number: 20140378653
    Abstract: This application relates to neurological inflammatory diseases, such as multiple sclerosis, and to methods of administering a Factor XII inhibitor to prevent, treat, or otherwise ameliorate the effects of a neurological inflammatory disease, such as multiple sclerosis. Agents and pharmaceutical compositions comprising agents which inhibit the activity of FXII are also provided.
    Type: Application
    Filed: January 31, 2013
    Publication date: December 25, 2014
    Inventors: Sven Meuth, Kerstin Goebel, Christoph Kleinschnitz, Brent McKenzie, Marc Nolte
  • Patent number: 8906633
    Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: December 9, 2014
    Assignee: Randox Laboratories Limited
    Inventors: Elouard Benchikh, Stephen Peter Fitzgerald, Paul John Innocenzi, Philip Andrew Lowry, Ivan Robert McConnell
  • Publication number: 20140348762
    Abstract: Described herein are methods for identifying a mammal having a heightened susceptibility to enamel erosion, together with kits therefor and uses and methods related thereto.
    Type: Application
    Filed: December 20, 2011
    Publication date: November 27, 2014
    Applicant: COLGATE-PALMOLIVE COMPANY
    Inventors: Lynette Zaidel, Steven Miller, Guy Carpenter, Gordon Proctor, David Bartlett, Rebecca Moazzez
  • Publication number: 20140302033
    Abstract: A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 or SEQ ID NO:2 and/or comprising a light chain variable domain having the sequence given in SEQ ID NO:3 or SEQ ID NO:4, in particular comprising a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 1 and SEQ ID NO:3 or a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 2 and SEQ ID NO:4. The disclosure also extends to polynucleotides encoding the antibodies or fragments, vectors comprising same and host cells capable of expressing the polynucleotides. The disclosure further includes pharmaceutical compositions comprising the antibodies or fragments and therapeutic used of any one of the same.
    Type: Application
    Filed: November 9, 2012
    Publication date: October 9, 2014
    Applicant: UCB PHARMA S.A.
    Inventors: Ralph Adams, Pavalli Bhatta, Sam Phillip Heywood, David Paul Humphreys
  • Publication number: 20140286964
    Abstract: The present invention provides methods for designing agents such as ligands capable of binding to a Janus kinase (Jak), particularly a Jak2 JH2, and especially a JH2 V617F, screening methods for identifying agents such as ligands and small molecules capable of binding to the same, and computer assisted methods for designing and identifying such agents. Further, the present invention provides methods for treating myeloproliferative neoplasias (MPNs) along with agents such as ligands and small molecules identified or designed using the methods described.
    Type: Application
    Filed: October 24, 2012
    Publication date: September 25, 2014
    Inventors: Stevan R. Hubbard, Rajintha M. Bandarayanake, Olli Silvennoinen, Daniela Ungureanu
  • Publication number: 20140248282
    Abstract: As a result of producing anti-DDR1 antibodies and conducting extensive studies on the antitumor activity thereof, antibodies that bind to the stalk domain in the amino acid sequence of human DDR1 were found to have a potent activity even when used alone compared to antibodies that bind to other domains. It was also found that the antibodies have one or more activities selected from the group consisting of: (i) an activity to suppress cell proliferation, (ii) an activity to inhibit cell migration, (iii) an activity to inhibit phosphorylation of DDR1 in cells, (iv) an activity to be taken up into cells, (v) an activity to decrease the expression level of DDR1 in cells, and (vi) an activity to decrease the expression level of TGF-? in cells.
    Type: Application
    Filed: August 23, 2012
    Publication date: September 4, 2014
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Mei Ono, Yuji Sano, Tsukasa Suzuki
  • Patent number: 8822653
    Abstract: Plasma kallikrein binding proteins and methods of using such proteins are described.
    Type: Grant
    Filed: January 6, 2011
    Date of Patent: September 2, 2014
    Assignee: Dyax Corp.
    Inventors: Daniel J. Sexton, Malini Viswanathan
  • Patent number: 8816055
    Abstract: Plasma kallikrein binding proteins and methods of using such proteins are described.
    Type: Grant
    Filed: January 6, 2012
    Date of Patent: August 26, 2014
    Assignee: Dyax Corp.
    Inventors: Daniel J. Sexton, Malini Viswanathan
  • Publication number: 20140234988
    Abstract: Non-mercaptalbumin-2 is used as a biomarker for diagnosing a medical condition associated with oxidative stress. A method for diagnosing a condition associated with oxidative stress includes determining the redox state of albumin at the cysteine residue at sequence position 34; quantifying the level of non-mercaptalbumin-2 present, non-mercaptalbumin-2 representing the albumin fraction irreversibly oxidized at cysteine 34; and comparing the result to a control level, wherein an elevated level of non-mercaptalbumin-2 as compared to the control level is indicative of the condition associated with oxidative stress.
    Type: Application
    Filed: August 14, 2012
    Publication date: August 21, 2014
    Applicant: MEDIZINISCHE UNIVERSITAET GRAZ
    Inventors: Carolin Lackner, Karl Oettl, Rudolf Stauber, Ruth Birner-Gruenberger
  • Publication number: 20140228546
    Abstract: The present invention relates to amino acid sequences that are capable of binding to serum albumin; to proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides.
    Type: Application
    Filed: June 14, 2012
    Publication date: August 14, 2014
    Applicant: Ablynx N.V.
    Inventors: Bruno Dombrecht, Peter Schotte, Cedric Josef Neotere Ververken
  • Patent number: 8802096
    Abstract: The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as the systemic inflammatory response syndrome (SIRS), and different degrees of sepsis including sepsis, severe sepsis, and septic shock.
    Type: Grant
    Filed: November 26, 2010
    Date of Patent: August 12, 2014
    Assignee: Inflarx GmbH
    Inventors: Renfeng Guo, Niels Christoph Riedemann, Yan Li, Beifen Shen
  • Publication number: 20140212433
    Abstract: The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Application
    Filed: March 5, 2014
    Publication date: July 31, 2014
    Applicant: Genentech, Inc.
    Inventors: ARTHUR HUANG, ROBERT KELLEY, HENRY LOWMAN, MENNO VAN LOOKEREN CAMPAGNE, CHARLES WINTER
  • Publication number: 20140194600
    Abstract: The present invention relates to binding molecules such as antibodies that specifically bind plasma coagulation factor XI and that inhibit factor XI activation and/or activity. The factor XI-binding molecules of the invention may used in methods for preventing or treating diseases, disorders and/or conditions that are mediated by factor XI activation and/or wherein inhibition of factor XI has a beneficial effect.
    Type: Application
    Filed: September 24, 2013
    Publication date: July 10, 2014
    Applicant: Prothix B.V.
    Inventor: Erik HACK
  • Publication number: 20140186365
    Abstract: Antibodies that specifically bind to an epitope on the serum albumin, including human and/or mouse serum albumin are provided. Nucleic acids encoding such antibodies and cells capable of expressing such antibodies are also provided.
    Type: Application
    Filed: March 14, 2013
    Publication date: July 3, 2014
    Applicants: Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center, Oncobiologics, Inc.
    Inventors: Matthew K. Robinson, John K. Cini, Jimson W. D'Souza
  • Patent number: 8759489
    Abstract: The present invention relates to an antibody that recognizes a first antibody, the antibody specifically recognizing one of a free first antibody and an antigen-binding first antibody. More specifically, the above antibody is a domino antibody that specifically recognizes and binds to an antigen-binding first antibody, or an antibody-unlocking antibody that specifically recognizes and binds to a free first antibody.
    Type: Grant
    Filed: August 24, 2011
    Date of Patent: June 24, 2014
    Assignees: Otsuka Pharmaceutical Co., Ltd., Tokyo University of Science
    Inventors: Takachika Azuma, Hisao Takizawa
  • Publication number: 20140140996
    Abstract: The invention relates to improved anti-serum albumin immunoglobulin single variable domains, as well as ligands and drug conjugates comprising such variable domains, compositions, nucleic acids, vectors and hosts.
    Type: Application
    Filed: January 30, 2014
    Publication date: May 22, 2014
    Applicant: Glaxo Group Limited
    Inventors: Edward COULSTOCK, Elena De Angelis, Haiqun Liu, Oliver Schon
  • Publication number: 20140087965
    Abstract: The present invention relates to a marker which can be used to diagnose a diabetic retinopathy patient and determine the progression of diabetic retinopathy, a composition for diagnosing diabetic retinopathy, which comprises an agent for measuring the level of a gene or protein associated with the marker, and the use thereof.
    Type: Application
    Filed: September 25, 2013
    Publication date: March 27, 2014
    Applicants: SNU R&DB FOUNDATION, LG ELECTRONICS INC.
    Inventors: Yunhee KU, Youngsoo KIM, Seungyeon SONG, Jonghwa JIN, Moosub KIM, Yongju YANG
  • Publication number: 20140081003
    Abstract: The present invention relates to methods and compositions for preventing incorporation of norleucine into proteins during recombinant protein production in bacteria. The present invention also provides microorganism host cells and nucleic acid molecules for use with the methods and compositions provided herein.
    Type: Application
    Filed: September 19, 2013
    Publication date: March 20, 2014
    Applicant: Genentech, Inc.
    Inventors: Michael W. Laird, Karthik Veeravalli
  • Patent number: 8663598
    Abstract: One embodiment of the disclosure provides an amino sequence of an anti-human transferrin receptor antibody, including: an amino sequence of a heavy chain variable region which is represented by SEQ ID NO.: 1 or SEQ ID NO.: 2, wherein the anti-human transferrin receptor antibody is capable of specifically binding to a human transferrin receptor.
    Type: Grant
    Filed: September 11, 2012
    Date of Patent: March 4, 2014
    Assignee: Industrial Technology Research Institute
    Inventors: Ming-Hua Yang, Min-Yuan Chou, Hsiang-Ching Wang
  • Publication number: 20130331282
    Abstract: Disclosed herein is a marker composition that includes sphingosine 1-phosphate (S1P) protein and that may be used to predict the risk of fracture or osteoporosis; a kit that includes an antibody that specifically binds to the S1P protein and that can be used to predict the risk of fracture or osteoporosis; and a method that can be used to obtain information that allows prediction of the risk of fracture or osteoporosis and includes measurements of S1P protein concentrations by measuring the binding of a S1P-specific antibody to S1P protein. The S1P protein disclosed herein is highly expressed in individuals with fracture, regardless of their bone mineral density. Accordingly, it may be useful as a biomarker of the risk of fracture or osteoporosis.
    Type: Application
    Filed: April 18, 2013
    Publication date: December 12, 2013
    Inventors: Jung Min Koh, Ghi Su Kim, Seung Hun Lee, Beom Jun Kim
  • Publication number: 20130323751
    Abstract: This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring urinary proteins can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury. Alternatively, the invention describes signature protein expression profiles to establish the probability of renal to recovery and/or renal non-recovery.
    Type: Application
    Filed: January 20, 2012
    Publication date: December 5, 2013
    Applicant: University of Pittsburgh - of the Common-Wealth System of Higher Education
    Inventors: Kai Singbartl, John A. Kellum, JR.
  • Publication number: 20130302333
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Application
    Filed: June 27, 2013
    Publication date: November 14, 2013
    Applicant: GENENTECH, INC.
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, JR., Micah Steffek, Christian Weismann, Menno Van Lookeren Campagne
  • Publication number: 20130266973
    Abstract: The invention provides anti-idiotypic HCMV antibodies as well as methods of using the same.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 10, 2013
    Inventors: Jo-Anne Hongo, Yanhong Li, Luna Liu, John Lowe, Mauricio Maia, Rajesh Vij, Terence Wong, Keyang XU
  • Publication number: 20130259801
    Abstract: A method for purifying serum amyloid P protein from fresh unfrozen plasma, includes recalcifying the fresh unfrozen plasma and separation by phenyl-type hydrophobic interaction chromatography. The serum amyloid P protein is also obtainable by the method and the use thereof for therapeutic treatment purposes. A method for determining amyloid deposits in a tissue or organ of a subject is also provided.
    Type: Application
    Filed: December 16, 2011
    Publication date: October 3, 2013
    Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Catherine Chenou, Jean-François Prost
  • Patent number: 8501427
    Abstract: The invention relates to antibodies, including monoclonal and polyclonal, or fragments thereof, which discriminate between the histidine and tyrosine isoforms of Complement Factor H and to their use in diagnostic methods and therapeutic treatments relating to Complement Factor H mediated diseases.
    Type: Grant
    Filed: January 23, 2008
    Date of Patent: August 6, 2013
    Assignee: University College Cardiff Consultants Limited
    Inventors: Bryan Paul Morgan, Claire Louise Harris, Svellana Hakobyan
  • Patent number: 8497350
    Abstract: The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: July 30, 2013
    Assignee: University of Iowa Research Foundation
    Inventor: Gregory S. Hageman
  • Patent number: 8486657
    Abstract: It is disclosed herein that antibodies specific for preproproteins or preproteins, which are synthesized by certain types of cells or tissues, can be used in immunohistochemistry assays to discriminate between the intracellular component of the protein (including the preproprotein, preprotein and/or proprotein forms of the protein) from the secreted component of the same protein. Accordingly, provided herein is an immunohistochemical method for specific detection of the intracellular form of a protein in a biological sample using an antibody specific for the preproprotein or preprotein form of the protein. In particular examples, the protein is albumin or an immunoglobulin light chain. Also disclosed herein are preproprotein-specific ore preprotein-specific antibodies that can be used to detect specific cell types, tissue lesions or other pathological foci and metastases by IHC. In particular, antibodies that specifically bind human preproalbumin, but do not bind the secreted form of albumin are disclosed.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: July 16, 2013
    Inventors: Xiaohong Cai, Thomas Cai
  • Publication number: 20130172535
    Abstract: The invention includes a process for extracting a target protein from E. coli cells that includes lowering the pH of a whole E. coli cell solution to form an acidic solution, disrupting the cells to release the protein into the acidic solution, and separating the cellular debris from the released protein to obtain a protein product enriched in the heterologous target protein. The invention also includes addition of a solubility enhancer.
    Type: Application
    Filed: June 29, 2012
    Publication date: July 4, 2013
    Inventor: Richard L. Gehant
  • Publication number: 20130157291
    Abstract: Disclosed is a diagnostic marker for lung cancer comprising Hp?R as an active ingredient. Because blood, which is relatively easy to sample, is employed as a specimen, the diagnostic kit and marker for lung cancer is very simple and does not subject patients to a load compared to conventional methods that are directed to a biopsy. In addition, the kit and marker of the present invention is useful in the early diagnosis of lung cancer thanks to its high diagnostic sensitivity and selectivity.
    Type: Application
    Filed: June 29, 2011
    Publication date: June 20, 2013
    Inventor: Il Han Kim
  • Publication number: 20130136736
    Abstract: The present invention relates to improved Nanobodies™ against von Willebrand Factor (vWF), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes.
    Type: Application
    Filed: January 4, 2013
    Publication date: May 30, 2013
    Applicant: Ablynx N.V.
    Inventor: Karen Silence
  • Publication number: 20130129746
    Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.
    Type: Application
    Filed: May 20, 2011
    Publication date: May 23, 2013
    Inventors: Elena De Angelis, Carolyn Enever, Haiqun Liu, Oliver Schon, Malgorzata Pupecka-Swider
  • Publication number: 20130115621
    Abstract: Disclosed are antibodies that selectively bind to blood coagulation factor FVIII, and highly sensitive immunological assays comprising these antibodies. Preferred assays can detect FVIII at about 3500-fold below the normal physiological levels, and have a wide array of applications including accurate monitoring of FVIII concentration in pharmaceutical products for treatment of blood coagulation disorders, and determination of FVIII levels in plasma of human patients, including those with blood coagulation disorders such as hemophilia.
    Type: Application
    Filed: July 18, 2012
    Publication date: May 9, 2013
    Applicant: The University of Vermont and State Agriculture College
    Inventors: Behnaz Parhami-Seren, Kenneth G. Mann, David N. Fass
  • Patent number: 8415113
    Abstract: A procedure for the identification of a functional disorder of the pancreas by the use of parts of all iso-enzymes of the pancreas elastase and of synthetic amino-acid sequences as antigens for obtaining specific antibodies, as well as their use in immuno-chemical test procedures.
    Type: Grant
    Filed: September 3, 1999
    Date of Patent: April 9, 2013
    Assignee: R-Biopharm AG
    Inventors: Hans-Werner Heinrich, Rainer Kleinert, Udo Meyer, Heinz-Jürgen Wagner
  • Publication number: 20130078245
    Abstract: The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting prophylactic or therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both.
    Type: Application
    Filed: August 17, 2012
    Publication date: March 28, 2013
    Applicant: The Regents of the University of Colorado, a body Corporate
    Inventors: V. Michael Holers, Joshua M. Thurman, Liudmila Kulik
  • Publication number: 20130052128
    Abstract: The present disclosure relates to binding agents (e.g. antibodies) that bind to and/or modulate the activity of a urokinase plasminogen activator receptor (uPAR/CD87), compositions comprising the antibodies, and methods involving use of the antibodies or compositions.
    Type: Application
    Filed: February 11, 2011
    Publication date: February 28, 2013
    Inventors: Charles S. Craik, Krishna Sai Duriseti, David H. Goetz
  • Publication number: 20130052202
    Abstract: The invention relates to high affinity human monoclonal antibodies, particularly those directed against isotypic determinants of immunoglobulin E (IgE), as well as direct equivalents and derivatives of these antibodies. These antibodies bind to their respective target with an affinity at least 100 fold greater than the original parent antibody. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.
    Type: Application
    Filed: July 27, 2012
    Publication date: February 28, 2013
    Inventors: Sanjaya Singh, Herren Wu, Catherine Foster
  • Publication number: 20130045180
    Abstract: Improved vaccines which include a nucleotide sequence that encodes immunomodulating protein operably linked to regulatory elements are disclosed. The improved vaccines include DNA vaccines, recombinant vaccines for delivering foreign antigen and live attenuated vaccines. Methods of immunizing individuals are disclosed. Compositions for and methods of treating individuals with autoimmune diseases are disclosed.
    Type: Application
    Filed: January 27, 2012
    Publication date: February 21, 2013
    Inventors: David B. Weiner, Jong J. Kim, Jeong-Im Sin
  • Publication number: 20130039925
    Abstract: A method of selecting a genus of therapeutic antibodies includes selecting antibodies with the following criteria; a) do inhibit cell lysis under conditions wherein the alternative pathway is isolated from the classical pathway; and b) do not inhibit cell lysis under conditions wherein the classical pathway is isolated from the alternative pathway; and c) do not inhibit cell lysis under conditions wherein the classical pathway and alternative pathway are active; and d) do inhibit C3b produced exclusively by the alternative pathway;
    Type: Application
    Filed: October 5, 2012
    Publication date: February 14, 2013
    Inventor: Rekha Bansal
  • Publication number: 20130011869
    Abstract: Provided are an antibody capable of specifically and accurately measuring digested products of stabilized fibrin (D-dimer), and a method and a reagent for measuring D-dimer using the antibody. The antibody specifically reacts with D-dimer, which is plasmin-digested products of stabilized fibrin, but does not react with fibrinogen or plasmin-digested products of fibrinogen, which include fragment X, fragment Y, fragment D1, and fragment E3, and does not react with dissociation products of DD/E monomer, which include fragment DD, fragment E1, and fragment E2.
    Type: Application
    Filed: March 31, 2011
    Publication date: January 10, 2013
    Applicant: Mitsubishi Chemical Medience Corporation
    Inventors: Yutaka Nagahama, Junko Nozaki, George Sakurai
  • Publication number: 20130004485
    Abstract: An isolated anti-properdin antibody or antigen binding portion thereof includes a heavy chain variable domain including the 3CDRs in SEQ ID NO: 1 and light chain variable domain including the 3 CDRS in SEQ ID NO: 9.
    Type: Application
    Filed: March 10, 2011
    Publication date: January 3, 2013
    Inventor: Rekha Bansal
  • Publication number: 20120328628
    Abstract: The present invention provides methods for generating antibodies to specific conformations of proteins. The conformation specific antibodies of the invention can be put to a variety of uses including diagnosis and treatment of diseases and for screening for compounds that induce conformational changes in proteins upon binding.
    Type: Application
    Filed: July 6, 2007
    Publication date: December 27, 2012
    Applicant: The Regents of the University of California
    Inventors: James A. Wells, Junjun Gao
  • Publication number: 20120321640
    Abstract: The invention provides new uses, compositions and methods of administration for specific binding agents to von Wiliebrand Factor (vWF) in patients with thromboembolic disorders and in particular new combined uses with thrombolytic agents such as tissue plasminogen activator in patients with thromboembolic disorders such as e.g. ischemic stroke. Furthermore, a new group of vWF binding agents and an improved Middle Cerebral Artery Thrombosis Model in guinea pigs to study the effects of stroke such as ischemia (oxygen and glucose depriviation) and hemorrhage (bleeding), in particular hemorrhage, are provided.
    Type: Application
    Filed: November 25, 2010
    Publication date: December 20, 2012
    Applicant: Ablynx N.V.
    Inventors: Maarten Van Roy, Hans Ulrichts
  • Publication number: 20120316324
    Abstract: A multivalent antibody fusion protein which comprises an immunoglobulin moiety, for example a Fab or Fab? fragment, with a first specificity for an antigen of interest, and further comprises two single domain antibodies (dAb) with specificity for a second antigen of interest which are a VH/VL pair, wherein the two single domain antibodies are linked by a disulfide bond. Also provided are particular dual specificity antibody fusion proteins and other antibody fragments which are stabilised by a disulfide bond.
    Type: Application
    Filed: September 24, 2010
    Publication date: December 13, 2012
    Applicant: UCB PHARMA, S.A.
    Inventors: Ralph Adams, Laura Hancock, Sam Phillip Heywood